Table 1 Demographic and clinical characteristics of patients
Stage 1Stage 2Probenecid(n = 35)p Value*
Allopurinol(n = 96)Benzbromarone(n = 27)
Demographics
    Age in years, mean (SD)58 (14)55 (16)58 (12)NS
    Male gender, %9210094NS
    Tophaceous gout, %413054NS
    Recurrent flares, %
            0–2/year40
            3–5/year33
            >5/year27
    Body mass index (kg/m2), mean (SD)29.3 (4.6)29.6 (3.4)29.4 (3.8)NS
    Creatinine clearance, %
        30–50 ml/min3
        50–80 ml/min322736NS
        >80 ml/min657364NS
    Centre, %
        Leeuwarden525246NS
        Enschede484854NS
Urate characteristics at baseline
    sUr (mmol/l), mean (SD)0.53 (0.07)0.55 (0.09)0.54 (0.07)NS
        Range0.39–0.760.43–0.760.39–0.72
    uUr (mmol/day), mean (SD)3.6 (1.6)4.1 (1.8)3.4 (1.6)NS
        Range1.2–10.02.2–9.81.3–10.0
    UrCl (ml/min/1.73 m2), mean (SD)3.8 (1.7)4.4 (1.9)3.6 (1.8)NS
        Range1.4–10.41.4–7.91.5–10.4
Type of excretor, %
    Underexcretor897894NS
    Normal excretor5133NS
    Overproducer693NS
  • *Comparison of stage 2 groups.

  • NS, non-significant (p>0.05); sUr, serum urate; UrCl, urate clearance; uUr, urate excreted in urine.